BR112015014701B8 - Derivados de benzimidazol e seus usos - Google Patents

Derivados de benzimidazol e seus usos

Info

Publication number
BR112015014701B8
BR112015014701B8 BR112015014701A BR112015014701A BR112015014701B8 BR 112015014701 B8 BR112015014701 B8 BR 112015014701B8 BR 112015014701 A BR112015014701 A BR 112015014701A BR 112015014701 A BR112015014701 A BR 112015014701A BR 112015014701 B8 BR112015014701 B8 BR 112015014701B8
Authority
BR
Brazil
Prior art keywords
derivatives
benzimidazole derivatives
kinases
present
inhibitors
Prior art date
Application number
BR112015014701A
Other languages
English (en)
Other versions
BR112015014701B1 (pt
BR112015014701A2 (pt
Inventor
Czardybon Wojciech
Brzózka Krzysztof
Galezowski Michal
Windak Renata
Milik Mariusz
Zawadzka Magdalena
Guzik Pawel
Wincza Ewelina
Prokop Marta
Wiklik Katarzyna
Sabiniarz Aleksandra
Marek Cholody Wieslaw
Horvath Raymond
Rzymski Tomasz
Original Assignee
Selvita Sa
Ryvu Therapeutics S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selvita Sa, Ryvu Therapeutics S A filed Critical Selvita Sa
Publication of BR112015014701A2 publication Critical patent/BR112015014701A2/pt
Publication of BR112015014701B1 publication Critical patent/BR112015014701B1/pt
Publication of BR112015014701B8 publication Critical patent/BR112015014701B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

DERIVADOS DE BENZIMIDAZOL COMO INIBIDORES DE QUINASE A presente invenção refere-se aos derivados de benzimidazóis de fórmula (I) como descrito aqui bem como composições farmacêuticas compreendendo os referidos derivados. Os derivados de acordo com a presente invenção são inibidores de serina/treonina e tirosina quinase, particularmente de PIM1-3- e DYRK1A-quinases e podem particularmente ser usados no tratamento de doenças ligadas a estas quinases, tais como por exemplo, leucemias, linfomas, tumores sólidos e distúrbios autoimunes.
BR112015014701A 2012-12-21 2013-12-20 Derivados de benzimidazol e seus usos BR112015014701B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1223265.8A GB201223265D0 (en) 2012-12-21 2012-12-21 Novel benzimidazole derivatives as kinase inhibitors
GB1223265.8 2012-12-21
PCT/EP2013/077754 WO2014096388A2 (en) 2012-12-21 2013-12-20 Novel benzimidazole derivatives as kinase inhibitors

Publications (3)

Publication Number Publication Date
BR112015014701A2 BR112015014701A2 (pt) 2017-07-11
BR112015014701B1 BR112015014701B1 (pt) 2022-11-01
BR112015014701B8 true BR112015014701B8 (pt) 2022-12-13

Family

ID=47682482

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015014701A BR112015014701B8 (pt) 2012-12-21 2013-12-20 Derivados de benzimidazol e seus usos

Country Status (22)

Country Link
US (2) US9388192B2 (pt)
EP (1) EP2935244B1 (pt)
JP (1) JP6169185B2 (pt)
KR (1) KR101779272B1 (pt)
CN (1) CN104936951B (pt)
AU (1) AU2013366513B2 (pt)
BR (1) BR112015014701B8 (pt)
CA (1) CA2896156C (pt)
CY (1) CY1120692T1 (pt)
DK (1) DK2935244T3 (pt)
ES (1) ES2688395T3 (pt)
GB (1) GB201223265D0 (pt)
HR (1) HRP20181429T8 (pt)
HU (1) HUE039376T2 (pt)
IL (1) IL239193A0 (pt)
LT (1) LT2935244T (pt)
MX (1) MX369589B (pt)
PL (1) PL2935244T3 (pt)
PT (1) PT2935244T (pt)
RS (1) RS57658B1 (pt)
SI (1) SI2935244T1 (pt)
WO (1) WO2014096388A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201223265D0 (en) 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP3094325B1 (en) 2014-01-14 2021-10-13 Takeda Pharmaceutical Company Limited Heteroaryls and uses thereof
EP3798214B1 (en) 2014-10-06 2022-09-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
MX2018002631A (es) * 2015-09-03 2019-02-07 Univ Arizona Inhibidores de molecula pequeña de dyrkia y usos de los mismos.
CA3019380A1 (en) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
ES2900263T3 (es) 2016-09-30 2022-03-16 Vertex Pharma Modulador de regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso de fabricación del modulador
JOP20190125B1 (ar) 2016-12-09 2022-03-14 Vertex Pharma مُعدِّل‏ لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل
US9855255B1 (en) 2017-05-26 2018-01-02 King Saud University Substituted naphthyridinyl hydrazines as anti-liver cancer agents
CA3066084A1 (en) 2017-06-08 2018-12-13 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
EP3654969A1 (en) 2017-07-17 2020-05-27 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
CA3078893A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
MA50413A (fr) 2017-10-19 2020-08-26 Amgen Inc Dérivés de benzimidazole et leurs utilisations
EP3720849A2 (en) 2017-12-08 2020-10-14 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
KR20210059663A (ko) * 2019-11-15 2021-05-25 가천대학교 산학협력단 신규한 벤즈이미다졸 유도체 및 이의 용도
CN113491691B (zh) * 2020-04-02 2023-04-14 深圳贝瑞生物医药科技有限公司 一种用于制备抗肿瘤药物或14-3-3η蛋白抑制剂的化合物
KR20210131855A (ko) * 2020-04-23 2021-11-03 런엑스 주식회사 R-point 조절 단백질 복합체를 유효성분으로 포함하는 폐암 치료용 약학적 조성물, 상기 복합체의 형성 여부를 이용한 폐암 치료제 스크리닝 방법 및 폐암 진단 방법
WO2023241627A1 (en) * 2022-06-15 2023-12-21 Insilico Medicine Ip Limited Cdk8/19 dual inhibitors and methods of use thereof
WO2024023278A1 (en) 2022-07-29 2024-02-01 Ryvu Therapeutics S.A. Cancer combination therapy including a flt3-inhibitor
WO2024023279A1 (en) 2022-07-29 2024-02-01 Ryvu Therapeutics S.A. Cancer combination therapy including a bcl-2 inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1469504A (fr) 1964-10-22 1967-02-17 Fisons Pest Control Ltd Composés insecticides
GB1122988A (en) * 1964-10-22 1968-08-07 Fisons Pest Control Ltd Benzimidazole derivatives
DE3227893A1 (de) * 1982-07-26 1984-01-26 Macherey-Nagel & Co Chemikalienhandel, 5160 Düren Verwendung von benzimidazolderivaten zum nachweis von blut und anderen peroxidatisch wirksamen substanzen in koerperfluessigkeiten und ausscheidungsprodukten, insbesondere als diagnostikum in form eines testpapiers
GB9600142D0 (en) * 1996-01-05 1996-03-06 Wellcome Found Chemical compounds
CA2303830A1 (en) * 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
PT1133477E (pt) * 1998-11-27 2004-06-30 Abbott Gmbh & Co Kg Benzimidazois substituidos e a utilizacao dos mesmos como inibidores da parp
WO2003020698A2 (en) * 2001-09-06 2003-03-13 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
EP1891048A1 (en) * 2005-06-11 2008-02-27 Vernalis (R&D) Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
CN102448458B (zh) * 2009-03-18 2015-07-22 小利兰·斯坦福大学理事会 治疗黄病毒科病毒感染的方法和组合物
EP2499117B1 (en) * 2009-11-12 2015-10-21 Selvita S.A. A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
JP2015532650A (ja) 2012-09-05 2015-11-12 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 非生物的植物ストレスに対する活性物質としての置換された２−アミドベンズイミダゾール類、２−アミドベンゾオキサゾール類および２−アミドベンゾチアゾール類またはそれらの塩の使用
GB201223265D0 (en) 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors

Also Published As

Publication number Publication date
GB201223265D0 (en) 2013-02-06
MX2015007057A (es) 2016-01-20
JP2016503779A (ja) 2016-02-08
LT2935244T (lt) 2018-10-25
US20170152249A1 (en) 2017-06-01
CN104936951A (zh) 2015-09-23
AU2013366513A1 (en) 2015-06-11
DK2935244T3 (en) 2018-09-10
PT2935244T (pt) 2018-10-22
JP6169185B2 (ja) 2017-07-26
US9388192B2 (en) 2016-07-12
ES2688395T3 (es) 2018-11-02
EP2935244A2 (en) 2015-10-28
IL239193A0 (en) 2015-07-30
CA2896156C (en) 2018-05-22
EP2935244B1 (en) 2018-06-27
HRP20181429T1 (hr) 2018-11-30
KR20150095908A (ko) 2015-08-21
WO2014096388A2 (en) 2014-06-26
PL2935244T3 (pl) 2019-02-28
HRP20181429T8 (hr) 2018-12-28
CA2896156A1 (en) 2014-06-26
SI2935244T1 (sl) 2019-01-31
CN104936951B (zh) 2018-02-06
AU2013366513B2 (en) 2016-09-01
RS57658B1 (sr) 2018-11-30
US20150336967A1 (en) 2015-11-26
BR112015014701B1 (pt) 2022-11-01
US10174013B2 (en) 2019-01-08
BR112015014701A2 (pt) 2017-07-11
KR101779272B1 (ko) 2017-09-18
HUE039376T2 (hu) 2018-12-28
MX369589B (es) 2019-11-13
WO2014096388A3 (en) 2014-08-21
CY1120692T1 (el) 2019-12-11

Similar Documents

Publication Publication Date Title
BR112015014701B8 (pt) Derivados de benzimidazol e seus usos
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
BR112018071097A2 (pt) compostos heterocíclicos como inibidores de ret cinase
BR112012020693A2 (pt) derivados de ciclobutano e metilciclobutano como inibidores de janus quinase
CY1122098T1 (el) Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
CR20130102A (es) Imidazopiridazinas sustituidas
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
CR20140397A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
BR112013001088A2 (pt) "derivados substituídos como inibidores a quinase de imidazoquinolina"
NZ715687A (en) Pyrimidine derivatives as kinase inhibitors
BR112015009942A2 (pt) derivados de tiofeno fundidos tricíclicos como inibidores de jak
BR112013025387A2 (pt) análogos substituídos da n-fenilpirimidin-2-amina como inibidores da quinase axl
BR112014029310A2 (pt) análogos da pirimidina heterocíclica como inibidores da tyk2
BR112015015635A2 (pt) inibidores de quinases de proteínas
UA112795C2 (uk) Біциклічні піразинонові похідні
BR112014019357A8 (pt) Derivados de tetra-hidro- quinazolinona como inibidores de tanc e parp
BR112013008523A2 (pt) compostos de piridazina carboxamida substituídos
PH12016500092A1 (en) New azabenzimidazole derivatives
GB201302704D0 (en) Therapeutic compounds
CL2018000856A1 (es) Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/12/2013, OBSERVADAS AS CONDICOES LEGAIS

B25D Requested change of name of applicant approved

Owner name: RYVU THERAPEUTICS S.A. (PL)

B25G Requested change of headquarter approved

Owner name: RYVU THERAPEUTICS S.A. (PL)